LYNK ' s LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis

HANGZHOU, China, May 16, 2023. Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ' Lynk Pharmaceuticals ' ), an innovative clinical stage company, announced that the Phase II clinical trial of LNK01001 in the treatment of rheumatoid arthritis...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news